Die Übersetzung dieser Seite ist experimentell und in Entwicklung. Wir freuen uns über Ihr !

Alphamab Oncology Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 6/6

Alphamab Oncology hat ein Gesamteigenkapital von CN¥1.7B und eine Gesamtverschuldung von CN¥250.0M, was einen Verschuldungsgrad von 15% ergibt. Die Gesamtaktiva und Gesamtpassiva betragen CN¥2.1B bzw. CN¥465.0M.

Wichtige Informationen

15.0%

Verhältnis von Schulden zu Eigenkapital

CN¥250.00m

Verschuldung

Zinsdeckungsgrad	n/a
Bargeld	CN¥1.41b
Eigenkapital	CN¥1.67b
Gesamtverbindlichkeiten	CN¥465.00m
Gesamtvermögen	CN¥2.14b

Jüngste Berichte zur Finanzlage

Recent updates

Alphamab Oncology's (HKG:9966) Shares Climb 27% But Its Business Is Yet to Catch Up

May 06

Optimistic Investors Push Alphamab Oncology (HKG:9966) Shares Up 27% But Growth Is Lacking

Mar 13

Subdued Growth No Barrier To Alphamab Oncology's (HKG:9966) Price

Jan 17

Slammed 40% Alphamab Oncology (HKG:9966) Screens Well Here But There Might Be A Catch

May 21

Newsflash: Alphamab Oncology (HKG:9966) Analysts Have Been Trimming Their Revenue Forecasts

Mar 01

Is Alphamab Oncology (HKG:9966) Using Debt Sensibly?

Oct 04

Is Alphamab Oncology (HKG:9966) A Risky Investment?

May 21

Rock star Growth Puts Alphamab Oncology (HKG:9966) In A Position To Use Debt

Oct 05

Is Alphamab Oncology (HKG:9966) Using Too Much Debt?

May 05

How Many Alphamab Oncology (HKG:9966) Shares Have Insiders Sold, In The Last Year?

Feb 09

Should Alphamab Oncology (HKG:9966) Be Disappointed With Their 19% Profit?

Dec 30

What Percentage Of Alphamab Oncology (HKG:9966) Shares Do Insiders Own?

Nov 25

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: 9966Die kurzfristigen Aktiva des Unternehmens (CN¥1.6B) übersteigen seine kurzfristigen Passiva (CN¥266.8M).

Langfristige Verbindlichkeiten: 9966Die kurzfristigen Vermögenswerte des Unternehmens (CN¥1.6B) übersteigen seine langfristigen Verbindlichkeiten (CN¥198.2M).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: 9966 über mehr Barmittel verfügt als seine Gesamtverschuldung.

Schulden abbauen: 9966 hatte vor 5 Jahren ein negatives Eigenkapital, ist jetzt aber positiv und hat sich somit verbessert.

Bilanz

Liquiditätsreserve-Analyse

Bei Unternehmen, die in der Vergangenheit im Durchschnitt Verluste gemacht haben, wird geprüft, ob sie über einen Liquiditätsvorlauf von mindestens einem Jahr verfügen.

Stabile Start- und Landebahn für Bargeld: 9966 auf der Grundlage seines derzeitigen freien Cashflows über eine ausreichende Liquiditätsreserve für mehr als 3 Jahre verfügt.

Vorhersage Cash Runway: 9966 über eine ausreichende Liquiditätsreserve für mehr als 3 Jahre verfügt, wenn der freie Cashflow weiterhin mit historischen Raten von 7 % pro Jahr zurückgeht

Alphamab Oncology Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 6/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

Is Alphamab Oncology (HKG:9966) Using Debt Sensibly?

Is Alphamab Oncology (HKG:9966) A Risky Investment?

Rock star Growth Puts Alphamab Oncology (HKG:9966) In A Position To Use Debt

Is Alphamab Oncology (HKG:9966) Using Too Much Debt?

Recent updates

Alphamab Oncology Presents Chinese Clinical Data of Anti-HER2 Bispecific ADC JSKN003 for the First Time at the 2024 ASCO Annual Meeting

Alphamab Oncology Provides Updates in Relation to A Phase III Clinical Trial of KN046 for the Treatment of Advanced PDAC

New major risk - Share price stability

Alphamab Oncology Announces First Patient Has Been Successfully Dosed in A Phase I Clinical Trial of JSKN016

Alphamab Oncology's (HKG:9966) Shares Climb 27% But Its Business Is Yet to Catch Up

Alphamab Oncology Announces Updates on Results of a Phase I Clinical Trial of JSKN003 for the Treatment of HER2-Expressing Advanced Solid Tumors for Presentation at 2024 AACR Annual Meeting

Alphamab Oncology Presented the Dose-Escalation Results from Jskn003 in Patients with Advanced/Metastatic Solid Tumors At Aacr

New minor risk - Share price stability

Consensus revenue estimates decrease by 12%, EPS upgraded

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

No longer forecast to breakeven

Alphamab Oncology, Annual General Meeting, Jun 12, 2024

Alphamab Oncology Announces the First Patient Dosed in Australia in the Clinical Study of Subcutaneous Formulation JSKN033

Alphamab Oncology Announces Results of Phase II Clinical Study of Kn046 Plus Chemotherapy as First-Line Treatment for Metastatic Nsclc Were Published in Cell Reports Medicine

Alphamab Oncology to Report Fiscal Year 2023 Results on Mar 28, 2024

Optimistic Investors Push Alphamab Oncology (HKG:9966) Shares Up 27% But Growth Is Lacking

Alphamab Oncology Announces Results of Phase II Clinical Study of KN046 in Combination with Nab-paclitaxel in TNBC were Published in Nature Communications

Subdued Growth No Barrier To Alphamab Oncology's (HKG:9966) Price

Alphamab Oncology Announces Phase I/II Clinical Trial of Jskn033 Independently Developed by Group for the Treatment of Human Epidermal Growth Factor Receptor

Alphamab Oncology Announces First Patient Dosed in Phase Iii Study of Jskn003 for the Treatment of Advanced Her2-Low Breast Cancer

Alphamab Oncology Announces Preliminary Results of a Phase I Clinical Trial of JSKN003 in Australia for the Treatment of Her2-Expressing Advanced Solid Tumors

New major risk - Revenue and earnings growth

New minor risk - Share price stability

Alphamab Oncology and CSPC Pharmaceutical Group Co., Ltd. Jointly Receive Breakthrough Therapy Designation on KN026 by CDE

Alphamab Oncology Announces Results of Two Studies of HER2 Bispecific Antibody KN026 At the European Society of Medical Oncology

New minor risk - Profitability

First half 2023 earnings released: CN¥0.042 loss per share (vs CN¥0.16 loss in 1H 2022)

Alphamab Oncology Announces Research Updates on KN046 and KN026 for Presentation At ESMO Congress 2023

Alphamab Oncology to Report First Half, 2023 Results on Aug 23, 2023

Alphamab Oncology Announces First Patient Successfully Dosed in Randomized, Controlled, Open-Label, Multi-Center, Phase III Clinical Trial of Kn026 in China

Alphamab Oncology Resignation of Xu Zhan Kevin as Non-Executive Director and Member of the Strategy Committee

Alphamab Oncology Updates Clinical Research Data for Kn026 in Combination with Kn046 in Her2-Positive Solid Tumors At the Asco 2023 Annual Meeting

Slammed 40% Alphamab Oncology (HKG:9966) Screens Well Here But There Might Be A Catch

Alphamab Oncology Updates in Relation to A Phase Iii Clinical Trial of Kn046 for the Treatment of Advanced SQ NSCLC

Consensus revenue estimates decrease by 13%, EPS upgraded

No longer forecast to breakeven

Newsflash: Alphamab Oncology (HKG:9966) Analysts Have Been Trimming Their Revenue Forecasts

Consensus revenue estimates decrease by 15%

Alphamab Oncology has completed a Follow-on Equity Offering in the amount of HKD 380.5 million.

Forecast to breakeven in 2025

Alphamab Oncology Presents Clinical Data of Kn026 Combined with Docetaxel as Neoadjuvant Treatment for Her2-Positive Early or Locally Advanced Breast Cancer At Sabcs 2022

Alphamab Oncology Presented Final Analysis of KN046 Combined with Nab-paclitaxel in the Treatment of mTNBC at SABCS 2022

Alphamab Oncology Announces Results from Three Clinical Studies of KN026 and KN046

Alphamab Oncology Receives IND Approval by NMPA for A Phase Ia/Ib Clinical Trial of JSKN003 for the Treatment of Advanced Solid Tumors

Is Alphamab Oncology (HKG:9966) Using Debt Sensibly?

Alphamab Oncology Announces First Patient Dosed in A Phase I Clinical Trial of JSKN003 (KN026-ADC) in Australia for the Treatment of Advanced Solid Tumors

Alphamab Oncology Presents the updated data from Phase 2 Clinical trial on KN046 Combined with platinum doublet chemotherapy as first-line(1L)treatment for NSCLC at ESMO 2022

Alphamab Oncology Announces Updates on Clinical Data of KN046 and KN026

Alphamab Oncology Announces Updates on Clinical Data of KN046 and KN026

Alphamab Oncology to Report First Half, 2022 Results on Aug 31, 2022

Alphamab Oncology Announces First Patient Dosed in Phase II Clinical Trial of KN046 Combined with Axitinib for the First-Line Treatment of Advanced NSCLC

Alphamab Oncology Announces Board and Committee Changes

Alphamab Oncology Announces First Patient Dosed in Phase I Trial of PD-L1/OX40 Bispecific Antibody KN052

Alphamab Oncology Announces First Patient Dosed in A Phase Ii Clinical Trial of Kn026 Combined with Palbociclib and Fulvestrant for the Treatment of Locally Advanced Unresectable or Metastatic Her2-Positive Breast Cancer

Is Alphamab Oncology (HKG:9966) A Risky Investment?

No longer forecast to breakeven

Alphamab Oncology Updates on Clinical Data of Kn046 in Combination with Kn026 for the Treatment of Her2-Positive Solid Cancer for Presentation at 2022 AACR Annual Meeting

No longer forecast to breakeven

Consensus forecasts updated

Alphamab Oncology Announces Completion of Phase III Clinical Trial of KN046

Alphamab Oncology, Annual General Meeting, Jun 10, 2022

Alphamab Oncology, Annual General Meeting, Jun 10, 2022

Alphamab Oncology to Present Clinical Data of KN026 Combined with KN046 in HER2-positive Solid Tumors at AACR 2022

Alphamab Oncology Announces Publication of Clinical Results of Kn026 in Her2-Positive Breast Cancer in Clinical Cancer Research

Alphamab Oncology Announces IND Approval of PD-L1/OX40 Bispecific Antibody KN052

Alphamab Oncology Announces First Patient Dosed in A Phase III Clinical Trial of KN046 for the Treatment of Advanced PDAC

Alphamab Oncology announces Enrollment Completed in Phase II Clinical Study of KN026 Combined with KN046

Alphamab Oncology and CSPC Pharmaceutical Group Co., Ltd. Announce Approval of IND Application for Pivotal Clinical Study of HER2 Bispecific Antibody KN026 Combined with Chemotherapy in Gastric Cancer

Forecast to breakeven in 2024

Alphamab Oncology Announces First Patient Dosed in the U.S. in a Phase II Pivotal Clinical Study of Kn046

Alphamab Oncology Announces IND Application for Phase 3 Registration Study of Kn046 in Combination with Chemotherapy for the Treatment of Pancreatic Cancer